Psychedelic News and Analysis Made Simple for Investors
Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.
Track the entire psychedelic market
We’ve developed the first all encompassing index to track the public psychedelic marketplace.
Explore the Index
Just Some of the Data we Cover
Latest News
Press
Apr 15
•
3 min read
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of allowance from the European Patent Office (EPO) for patent application 19827430.0 for its lead chronic…
Press
Vancouver, Canada, April 08, 2025 — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the publication of an international patent application in collaboration with Yissum Research Development Company of the Hebrew…
Apr 15
•
2 min read
Press
New York, New York–(Newsfile Corp. – April 8, 2025) – Psyence BioMed (NASDAQ: PBM) (“Psyence BioMed” or the “Company”) today announced the signing of a Letter of Intent (LOI) with Southern Star Research Pty Ltd, a premier Australian contract research organization (CRO). This collaboration will accelerate Psyence BioMed’s ongoing Phase IIb psilocybin clinical trial in…
Apr 15
•
3 min read
Press
Vancouver, British Columbia –TheNewswire -7 April, 2025–MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6),(the “Company” or “MindBio”),is a clinical stage biopharmaceutical company targeting depressive illnesses currently dosing in multiple Phase 2B clinical trials. The Company today has issued 3,428,571 common share purchase warrants (the “Warrants”), to Haywood Securities in connection with the completion of strategic investment…
Apr 15
•
2 min read
Press
Vancouver, British Columbia – TheNewswire – April 2, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company pioneering new treatments for mental health conditions announces that it has adopted a new equity incentive plan (the “New Plan”). The New Plan is a 20% rolling equity incentive plan that provides for the issuance…
Apr 3
•
2 min read
Press
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it…
Apr 3
•
4 min read
Press
Vancouver, Canada, April 01, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today the launch of its Electronic Data Capture (EDC) system to support its Phase I/II clinical trial of its MEAI-based…
Apr 3
•
3 min read
Explore the Psychedelic Landscape
Learn more about the psychedelic companies changing the industry.